Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib.

DL, White; J, Radich; S, Soverini; VA, Saunders; AK, Frede; P, Dang; D, Cilloni; P, Lin; L, Mongay; R, Woodman; P, Manley; C, Slader; DW, Kim; F, Pane; G, Martinelli; G, Saglio; TP, Hughes

doi:10.3324/haematol.2011.056457

Public

Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib.

Shared by NobleBlocks on Dec 29, 2011 • 12:00 AM UTC

Authors:

White DL

Radich J

Soverini S

Abstract

Background The functional activity of the organic cation transporter 1 (OCT-1) protein (OCT-1 activity) is an excellent predictor of molecular response and progression-free survival in patients with newly diagnosed chronic phase chronic myeloid leukemia treated with imatinib as front-line therapy.De...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!